MorphoSys AG (MOR) Social Stream
MORPHOSYS AG (MOR) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering MOR.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-12 | 3 | $26 | $16 | $21.333 | $9.41 | 126.71% |
| 2021-11-12 | 3 | $25 | $16 | $21 | $9.41 | 123.17% |
| 2022-01-04 | 3 | $25 | $11 | $19.333 | $9.41 | 105.45% |
| 2022-03-21 | 2 | $22 | $11 | $16.5 | $9.41 | 75.35% |
| 2022-04-04 | 2 | $11 | $11 | $11 | $9.41 | 16.9% |
| 2022-05-11 | 2 | $11 | $9 | $10 | $9.41 | 6.27% |
| 2022-05-20 | 2 | $10 | $9 | $9.5 | $9.41 | 0.96% |
| 2022-06-24 | 2 | $9 | $7 | $8 | $9.41 | -14.98% |
| 2022-08-04 | 2 | $9 | $7.1 | $8.05 | $9.41 | -14.45% |
| 2022-08-10 | 4 | $8.3 | $7.1 | $7.7 | $9.41 | -18.17% |
| 2022-11-18 | 5 | $15 | $5 | $9.033 | $9.41 | -4.01% |
| 2022-11-21 | 6 | $15 | $4.5 | $8.166 | $9.41 | -13.22% |
| 2023-01-03 | 6 | $15 | $2.9 | $7.466 | $9.41 | -20.66% |
| 2023-04-26 | 6 | $15 | $2.9 | $7.033 | $9.41 | -25.26% |
| 2023-05-08 | 6 | $15 | $2.9 | $7.133 | $9.41 | -24.2% |
| 2023-05-18 | 6 | $15 | $3.3 | $7.266 | $9.41 | -22.78% |
| 2023-06-16 | 7 | $17 | $3.5 | $11.375 | $9.41 | 20.88% |
| 2023-08-10 | 8 | $17 | $3.5 | $11.375 | $9.41 | 20.88% |
| 2023-08-17 | 8 | $17 | $3.7 | $11.425 | $9.41 | 21.41% |
| 2023-09-25 | 8 | $17 | $3.7 | $10.99 | $9.41 | 16.79% |
| 2023-10-13 | 8 | $17 | $9.2 | $11.362 | $9.41 | 20.74% |
| 2023-11-21 | 8 | $17 | $9.2 | $12.49 | $9.41 | 32.73% |
| 2023-11-22 | 8 | $17 | $4.75 | $11.59 | $9.41 | 23.17% |
| 2023-12-05 | 8 | $17 | $4.75 | $11.29 | $9.41 | 19.98% |
The Trend in the Analyst Price Target
Over the past 19 months, MOR's average price target has gone up $1.29.
Over the past 48 weeks, MOR's average upside potential has been 58.49%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-04-26 | 6 | 15 | 2.9 | 7.033 | 5.16 | 36.3% |
| 2023-06-16 | 7 | 15 | 3.5 | 9.500 | 7.72 | 23.06% |
| 2023-06-16 | 7 | 17 | 3.5 | 11.375 | 7.72 | 47.34% |
| 2023-10-13 | 8 | 17 | 9.2 | 11.362 | 6.50 | 74.8% |
| 2023-11-21 | 8 | 17 | 9.2 | 12.490 | 4.55 | 174.51% |
MOR Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.06 | 4 | 1 | 2 | 1 | 1 | 8 |
The Trend in the Broker Recommendations
Over the past 31 weeks, MOR's average broker recommendation rating improved by 2.21.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how MORPHOSYS AG fares relative to all US stocks, note that its average analyst price target is higher than 384.34% of that group.
- MOR has a lower variance in analysts' estimates than -1974.8% of all US stocks.
- MORPHOSYS AG's upside potential (average analyst target price relative to current price) is higher than 592.64% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, MORPHOSYS AG's number of analysts covering the stock is higher than 865.86% of them.
Stocks similar to MORPHOSYS AG in the Pharmaceutical Products industry regarding analyst recommendations and price targets are RCUS, ZYME, and HCM.
View All Top Stocks by Price Target
What is the outlook for MOR? Use POWR Ratings for clearer insight into price direction.